FDA
-
-
-
-
-
-
-
Reviva publishes vocal biomarker data from brilaroxazine Phase 3 trial
-
-
-
-
-
-
-
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
-
-
-
-
-
-
-
Applied Therapeutics Inc. (APLT) Appoints John H. Johnson as Executive Chairman
-
-
-
-
-
-
-
Reviva Pharmaceuticals (RVPH) Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
-
-
-
-
-
-
-
Reviva (RVPH) Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
-
-
-
-
-
-
-
Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
-
-
-
-
-
-
-
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
-
325,142 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

